Jan. 16 at 1:31 PM
Good share and highlights osteoporosis/ CNS as addtl modalities C5a could support.
“Significantly reduce the amount of hormones and reduce the side effects of infection, osteoporosis.”
At present, many C5aR targeted drugs have entered clinical practice:
● Avacopam: the first oral small molecule C5aR antagonist, which has been approved for AAV in many countries;
$AMGN
● Vilobelimab: anti-C5a monoclyb, which is urgently authorized by the FDA for severe COVID-19;
$IFRX
●KP104: Dual-functional antibody, blocking C5 lysis and C5a binding at the same time, P2.3, Paroxysmal Nocturnal Hemoglobinuria (PNH) and renal diseases such as IgA nephropathy. Kira Phara US, private
●PMX-205: Cyclopeptide small molecules, exploring new indications for skin diseases, Alzheimer's disease, etc. (Alsonex, 2026 1b for ALS trial pending), Australia private.
$PFE
$BIIB
https://investors.biogen.com/news-releases/news-release-details/biogen-acquire-novel-clinical-stage-asset-application-alzheimers
